MAP2K7 and hepatocellular carcinoma: Further analysis revealed that the MEK inhibitors U0126 and AZD6244 modulated the MAPK pathway by increasing the p-MEK levels and decreasing p-ERK levels, downregulating the expression of ABCC1 and ABCC3 in HCC [59].